Columbus Cardiology Associates

Physicians & Surgeons, Cardiology, Physicians & Surgeons, Physicians & Surgeons, Surgery-General

Be the first to review!

OPEN NOW

Today: 9:00 am - 5:00 pm

(212) 376-3180Call Visit WebsiteVisit Website Map & DirectionsDirections425 W 59th StNew York, NY 10019 Write a ReviewWrite Review

Is this your business?

Customize this page.

Claim This Business

Hours

Regular Hours

Mon - Fri:	9:00 am - 5:00 pm

Places Near New York with Physicians & Surgeons, Cardiology

Long Island City (4 miles)
Astoria (5 miles)
Hoboken (5 miles)
Jersey City (9 miles)
Elmhurst (10 miles)
Forest Hills (13 miles)
Brooklyn (14 miles)
Hackensack (14 miles)
Flushing (14 miles)
Bronx (14 miles)

Accepted Insurance

Columbus Cardiology Associates has not yet specified accepted insurance plans.

Specialties

Columbus Cardiology Associates has not yet specified any specialties.

More Info

Extra Phones: Fax: (212) 376-3190
Payment method: master card, visa
Location: Mount Sinai Roosevelt
Other Link: https://nyulangone.org/locations/nyu-langone-ambulatory-care-west-side
Categories: Physicians & Surgeons, Cardiology, Physicians & Surgeons, Physicians & Surgeons, Surgery-General

GalleryView all (1)

Gallery Image Number 1

Reviews

Hi there!
Be the first to review!

Click to Rate

Details

Phone: (212) 376-3180

Address: 425 W 59th St, New York, NY 10019

Website: https://nyulangone.org/locations/nyu-langone-ambulatory-care-west-side

People Also Viewed

View similar Physicians & Surgeons, Cardiology

Suggest an Edit

Columbus Cardiology Associates

General Practitioners

Cryotherapy
Do I still have cancer? This is a question one of my favorite patients has begun asking me, five years after I diagnosed him with prostate cancer. In the intervening time, he hasn’t had his prostate removed. He hasn’t had external beam radiation, radioactive “seeds,” or cryotherapy. Since his prostate cancer was not aggressive looking under the microscope (it was …
Medical Weight Loss
Actually, it would be inaccurate to say “we” decided. He decided. It’s not that easy to look at a young, healthy guy and say,”you have prostate cancer; let’s watch it.” We are of course worried that the prostate cancer could leave the prostate, spreading to bone or other organs in the body and growing there. It can cause pain, fracture bones, put pressure on nerves and the spinal chord, cause anemia, weight loss, and death. But, most men are diagnosed with prostate cancer long before this, and they feel healthy. There is a group of men who we can diagnose with prostate cancer who will grow old, never suffering the ill effects of prostate cancer. Presumably, they would have good risk prostate cancer, a low PSA, a prostate that doesn’t feel hard or nodular. And they would have a low volume of prostate cancer. My patient had a “12 core” biopsy – meaning biopsies taken from 12 spots in the prostate. Only 1/12 showed prostate cancer, and it was present in less than 5% of that core. That’s the guy we worry about over treating. If you look at all they guys like Michael, some of them will make it through their entire life without feeling the ill effects of prostate cancer. Some won’t. This is the group that likely “blurs” the results of our prostate cancer screening, and makes people wonder if looking for prostate cancer causes more harm than good (but that’s a different subject). Michael got a second opinion from a doctor I respect, and we embarked upon a program of Active Surveillance. He decided he was more concerned about risks and side effects from radiation or surgery than the cancer. This meant we would biopsy him every 6 months at first, then every year. We would follow his exam and PSA. If things got worse – if he “progressed” to Gleason 7, or an abnormal rectal exam, or a consistently rising PSA, or a higher volume, we could consider treating him. He has faired well. His PSA is not above his initial level, and his exam is still normal. Most importantly, he had one biopsy early on that showed small volume, good risk disease, but all the others showed no cancer at all. Hence the question: “Do I still have cancer?” And more recently, “Is there a point at which I can stop having biopsies?”

Urology
Craig F. Nobert, MD, is Associate Director of Laparoscopic and Robotic Urology at Mount Sinai West Hospital. He was appointed Director of Laparoscopic Urologic Surgery in the Department of Urology at St. Luke’s and Roosevelt Hospitals in 2004.
Kidney Cancer
To be clear, the authors didn’t actually employ their proposed strategy. This study looked back at 151 patients who had a biopsy and then went on to surgery regardless of what was found. Even if they had a biopsy that predicted that the mass was not cancer, or if it added no useful information they still had surgery. All the masses were less than 4 cm. The biopsy often predicted not only cancer, but specific types of kidney cancer, or different levels of aggressiveness. Since everything was taken out, the authors could judge the accuracy of these predictions. The authors then created a “what if” scenario to see how a decision tree for deciding who to operate on or who to watch would work. The decision tree combined biopsy information and size to guide the decision.
Prostate Cancer
Those are great questions. I told him that I would always consider him to have prostate cancer. This is based upon my understanding of the biology of tumors – cancer cells are not known to spontaneously disappear. But the time period over which the changes required for progression is variable, and may be longer than his lifetime. The second question – can we stop the biopsies – has go to be answered “no,” because the real answer is “I don’t know yet.”. Michael and I have had many discussions about active surveillance. One point I am always careful to bring up is that the whole idea of active surveillance is new.

Anxiety

Ultrasound
Most kidney tumors are discovered when a patient gets a CAT scan, ultrasound, or MRI for an unrelated problem. Because of this, many tumors are small. In a past era, tumors smaller than 3-4 cm were often observed. The risks of the alternative (removing the entire kidney through a flank incision ) was considered worse than the risk of spread during observation. Biopsy was shown to be so poorly predictive of a tumor’s ability to spread that it was not considered to add useful information beyond that of size alone.
MRI

Vasectomy
Robotic Surgery
Dr. Nobert has served as Chief Resident at the Sanford Weill Medical School of Cornell University in the James Buchanon Brady Department of Urology, and at The North Shore University Hospital in Manhasset Long Island. In that capacity, he also served as a clinical fellow at Memorial Sloan Kettering Hospital in New York. During that time, he conducted research in genetic alterations of hormone-refractory prostate cancer, which led to several publications. He has also received specialized training in Laparoscopic Surgery and Robotic Surgery and has presented demonstration films for the use of these techniques in Urology at the American Urologic Association meeting in May of 2004. Dr. Nobert received his Medical Degree from Tufts University School of Medicine and holds a Master’s of Science degree in Molecular Biology from San Diego State University, where he conducted research on signal transduction factor binding sites of genes. He completed a Bachelor of Arts degree in Humanities and Biochemistry from Columbia University. He also has worked as a Research Associate at Amgen Incorporated conducting research directed at the identification and characterization of novel cytokines. Dr. Nobert is certified by the American Board of Urology in Adult and Pediatric Urology.

Plastic Surgeons

Laparoscopic Surgery

View All Services

Provided by